Gonzalo Spera

Neoadjuvant Trastuzumab Emtansine and Pertuzumab in Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Three-Year Outcomes From the Phase III KRISTINE Study

Sara A. Hurvitz, Miguel Martín, Kyung Hae Jung et al. · Journal of Clinical Oncology · 2019 · 248 citations · Full text

Medicine, Oncology, Pharmacology +17

Beta blockers and improved progression-free survival in patients with advanced HER2 negative breast cancer: a retrospective analysis of the ROSE/TRIO-012 study

Gonzalo Spera, Rodrigo Fresco, Hoki Fung et al. · Annals of Oncology · 2017 · 72 citations

Medicine, Oncology, Pharmacology +9

NATALEE: Phase III study of ribociclib (RIBO) + endocrine therapy (ET) as adjuvant treatment in hormone receptor–positive (HR+), human epidermal growth factor receptor 2–negative (HER2–) early breast cancer (EBC).

Dennis J. Slamon, Peter A. Fasching, Ravindranath Patel et al. · Journal of Clinical Oncology · 2019 · 54 citations

Medicine, Endocrinology, Pharmacology +11

Neoadjuvant palbociclib plus either giredestrant or anastrozole in oestrogen receptor-positive, HER2-negative, early breast cancer (coopERA Breast Cancer): an open-label, randomised, controlled, phase 2 study

Sara A. Hurvitz, Aditya Bardia, Vanesa Quiroga et al. · The Lancet Oncology · 2023 · 35 citations · Full text

Medicine, Oncology, Pharmacology +17

Neoadjuvant giredestrant (GDC-9545) plus palbociclib (P) versus anastrozole (A) plus P in postmenopausal women with estrogen receptor–positive, HER2-negative, untreated early breast cancer (ER+/HER2– eBC): Final analysis of the randomized, open-label, international phase 2 coopERA BC study.

Peter A. Fasching, Aditya Bardia, Vanesa Quiroga et al. · Journal of Clinical Oncology · 2022 · 31 citations

Medicine, Oncology, Pharmacology +17